Page 900 - Traité de chimie thérapeutique 6 Médicaments antitumoraux

858 NOUVELLES MOLÉCULES ET PERSPECTIVES

BOGER D.L. et al., Parallel synthesis and evatuation of 132 (+)-1,2,9,9a-tetrahydrocyclo-
propa[c)benz[e]indot-4-one (CBI) analogues of CC-1065 and the duocarmycins defi-
ning the contribution of the DNA-binding domain, J. Org. Chem., 2001, 66, 6654-6661.
ALBRECHT B.K., WILLIAMS R.M., Entry into the bi-aryl moiety of the TMC-95 pro-
teasome inhibitors via the Stille protocole, Tetrahedron Lett., 2001, 42, 2755-2757.
HERBERICH B. et al., Sequential Staudinger/Pictet-Spengler cyclization strategy forthe
construction of tetrahydroisoquinolines of the bioxalomycin and ecteinascidin famity
of atkaloids, Tetrahedron Lett., 2001, 42, 543-546.
HEL. et al., Novel motecutes that interact with microtubules and have functional activity
similar to Taxol, Drug Discovery To-day, 2001, 6, 1153-1164.
GAUKROGER K. et al., Novel syntheses of cis and trans isomers of combretastatin A-4,
J. Org. Chem., 2001, 66, 8135-8138.
INOUE M. et al., Stereocontrolled synthesis of the northern part of potent proteasome
inhibitor TMC-95A, Org. Lett., 2001, 3 (18), 2863-2865.
TAKEBAYASHI Y. et al., Antiproliferative activity of ecteinascidin 743 is dependent upon
transcription-coupled nucleotide-excision repair, Nat. Med., 2001, 7, 961-966.
ENDO A. et al., Total synthesis of ecteinascidine 743, J. Amer. Chem. Soc., 2002, 124,
6552-6554.
ZHOU B. et al., Studies directed to the total synthesis of ET 743 and analogues theoreof:
an expeditious route to the ABFGH subunit, Org. Lett., 2002, 4, 43-46.
NECKERS L., Hsp90 inhibitors as novel cancer chemotherapeutic agents, Trends in
Molecular Medicine, 2002, 8 (4), S55-61.
SCOTT J.O. et WILLIAMS R.M., Chemistry and biotogy of tetrahydroisoquinoline anti-
tumor antibiotics, Chem. Rev., 2002, 102, 1669-1730.
D'INCALCI. et al., Unique features of the mode of action of ET-743, Oncologist, 2002,
7, 210-216.
SIGNALISATION ET KINASES
KONNO H., Antitumor effect of the angiogenesis inhibitor TNP-470 on human digestive
organ malignancy, Cancer Chemother. Pharmacol., 1999, 43 (suppl.), S85-S89.
BOSCHELLI D.H., Small molecute inhibitors of receptor tyrosine kinases, Drugs of the
Future, 1999, 24 (5), 515-537.
BOGER D.L., GOLDBERG J., Cytokine receptor dimerization and activation: prospects
for smalt molecule agonists, Bioorg. Med. Chem., 2001, 9, 557-562.
1 2
BASELGA R., AVERBUCH S.D., 2D1839 (« tressa ») • as an anticancer agent, Drugs,
2000, 60 (suppl.), 33-40.
VINCENT P.W. et al., Anticancer efficacy of the irreversible EGFr tyrosine kinase inhibitor
PD 0169414 against human tumor xenografts, Cancer Chemother. Pharmacol., 2000,
45, 231-238.
ZHANG N. et al., MEK (MAPKK) inhibitors. Part 2 : structure-activity relationships of
4-anilino-3-cyano-6,7-dialkoxyquinolines, Bioorg. Med. Chem. Lett., 2001, 11, 1407-
1410.
JAE H.-S. et al., Pyrrolidine-3-carboxylic acids as endothelin antagonists. 5. Highly
selective, potent, and orally active ET, antagonists, J. Med. Chem., 2001, 44, 3978-
3984.